Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial

PURPOSE: Patients with stage III non-small-cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT) in low- and middle-income countries (LMIC) continue to have a poor prognosis. It is known that FDG PET/CT improves staging, treatment selection and target volume delineation (TVD), and although i...

Descripción completa

Detalles Bibliográficos
Autores principales: Konert, T., Vogel, W. V., Paez, D., Polo, A., Fidarova, E., Carvalho, H., Duarte, P. S., Zuliani, A. C., Santos, A. O., Altuhhova, D., Karusoo, L., Kapoor, R., Sood, A., Khader, J., Al-Ibraheem, A., Numair, Y., Abubaker, S., Soydal, C., Kütük, T., Le, T. A., Canh, N. X., Bieu, B. Q., Ha, L. N., Belderbos, J. S. A., MacManus, M. P., Thorwarth, D., Hanna, G. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717604/
https://www.ncbi.nlm.nih.gov/pubmed/31367906
http://dx.doi.org/10.1007/s00259-019-04421-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717604/
https://www.ncbi.nlm.nih.gov/pubmed/31367906
http://dx.doi.org/10.1007/s00259-019-04421-5

Ejemplares similares